This Unstoppable Stock Has Gained 100,203% Over The Last 50 Years, Creating Many Millionaires in the Process. Here Are 3 Reasons I Think It Will Continue to Create Generational Wealth.
https://www.fool.com/investing/2024/09/08/this-unstoppable-stock-has-gained-100203-over-the/?source=iedfolrf0000001
Sep 08, 2024 - Eli Lilly has been a big-time winner for investors over the last several decades, and there are many reasons to believe the company is at the forefront of many new growth stories.
0
Beyond Mounjaro and Zepbound: 6 Other Drugs That Could Be Blockbusters for Eli Lilly
https://www.fool.com/investing/2024/09/08/beyond-mounjaro-and-zepbound-eli-lilly/?source=iedfolrf0000001
Sep 08, 2024 - This drugmaker should have a basketful of growth drivers over the next decade.
0
Eli Lilly's Weekly Insulin Shot Meets Two Late-Stage Study Goals
https://www.zacks.com/stock/news/2333037/eli-lilly-s-weekly-insulin-shot-meets-two-late-stage-study-goals?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2333037
Sep 06, 2024 - Data from two late-stage studies show that LLY's once-weekly insulin injections achieved results that are similar to daily insulin shots.
0
Pharma Stock Roundup: EU Nod for Expanded Use of MRK's Keytruda & More
https://www.zacks.com/stock/news/2332784/pharma-stock-roundup-eu-nod-for-expanded-use-of-mrk-s-keytruda-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2332784
Sep 06, 2024 - European Commission approves expanded use of Merck's Keytruda in bladder cancer. Sanofi & Lilly announce data from phase III studies on pipeline candidates.
0
NVS or LLY: Which Is the Better Value Stock Right Now?
https://www.zacks.com/stock/news/2331584/nvs-or-lly-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2331584
Sep 04, 2024 - NVS vs. LLY: Which Stock Is the Better Value Option?
0
ATHA Stock Tanks as Alzheimer's Study Fails to Meet Primary Goal
https://www.zacks.com/stock/news/2331539/atha-stock-tanks-as-alzheimer-s-study-fails-to-meet-primary-goal?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2331539
Sep 04, 2024 - Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.
0
Merck's Keytruda & Padcev Combo Gets EU Nod for Urothelial Carcinoma
https://www.zacks.com/stock/news/2331488/merck-s-keytruda-padcev-combo-gets-eu-nod-for-urothelial-carcinoma?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2331488
Sep 04, 2024 - MRK's Keytruda gets approval in combination with Astellas and Pfizer's Padcev for treating first-line advanced urothelial carcinoma.
0
3 Big Winners from the Q2 Earnings Season: LLY, LMT, META
https://www.zacks.com/commentary/2329973/3-big-winners-from-the-q2-earnings-season-lly-lmt-meta?cid=CS-ZC-FT-investment_ideas-2329973
Sep 03, 2024 - The 2024 Q2 earnings season is slowly grinding to a halt, with the majority of S&P 500 companies already delivering quarterly results. And during the period, these three companies stole the spotlight.
0
Viking Surges 342% in the Past Year: How Should You Play the Stock?
https://www.zacks.com/stock/news/2330874/viking-surges-342-in-the-past-year-how-should-you-play-the-stock?cid=CS-ZC-FT-analyst_blog|most_popular_stocks-2330874
Sep 03, 2024 - VKTX stock continues to generate phenomenal returns, driven by encouraging development of its obesity and NASH drugs, which are nearing late-stage development.
0
Bayer Presents Encouraging Data From Late-Stage Cardiovascular Study
https://www.zacks.com/stock/news/2330383/bayer-presents-encouraging-data-from-late-stage-cardiovascular-study?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2330383
Sep 02, 2024 - BAYRY's late-stage FINEARTS-HF study on finerenone show statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure.
0